scholarly journals Prevalence, antimicrobial resistance and serotype distribution of group B streptococcus isolated among pregnant women and newborns in Rabat, Morocco

2018 ◽  
Vol 67 (5) ◽  
pp. 652-661 ◽  
Author(s):  
Cinta Moraleda ◽  
Rachid Benmessaoud ◽  
Jessica Esteban ◽  
Yuly López ◽  
Hassan Alami ◽  
...  
Keyword(s):  
Antimicrobial Resistance ◽  
Pregnant Women ◽  
Group B Streptococcus ◽  
Serotype Distribution ◽  
Group B

scholarly journals Group B streptococcus colonization, antibiotic susceptibility, and serotype distribution among Saudi pregnant women

2020 ◽  
Vol 52 (1) ◽  
pp. 70
Author(s):  
Amr Mohamed Mohamed ◽  
Mubashir Ahmad Khan ◽  
Aftab Faiz ◽  
Jawwad Ahmad ◽  
Elsheikh Babiker Khidir ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Antibiotic Susceptibility ◽  
Group B Streptococcus ◽  
Serotype Distribution ◽  
Group B

scholarly journals Group B Streptococcus colonization rate and serotype distribution among pregnant women and their newborns at Adama Hospital Medical College, Ethiopia

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Musa Mohammed Ali ◽  
Daniel Asrat ◽  
Demissie Assegu Fenta ◽  
Tolossa Eticha Chaka ◽  
Yimtubezinash Woldeamanuel
Keyword(s):  
Pregnant Women ◽  
Group B Streptococcus ◽  
Colonization Rate ◽  
Serotype Distribution ◽  
Medical College ◽  
Hospital Medical ◽  
Group B

Serotype distribution and antibiotic susceptibility of group B streptococci in pregnant women

2009 ◽  
Vol 138 (7) ◽  
pp. 979-981 ◽  
Author(s):  
A. DHANOA ◽  
R. KARUNAKARAN ◽  
S. D. PUTHUCHEARY
Keyword(s):  
Pregnant Women ◽  
Neonatal Sepsis ◽  
Antibiotic Susceptibility ◽  
Group B Streptococcus ◽  
Prevention Strategies ◽  
Serotype Distribution ◽  
Group B Streptococci ◽  
Birth Canal ◽  
Group B

SUMMARYGroup B streptococcus (GBS) is a leading cause of neonatal sepsis and is usually acquired via the woman's birth canal. GBS serotypes isolated from 200 pregnant women were determined. Serotypes V (19%) and VI (17%) were the most frequent followed by serotypes III (12%), Ia (11·5%) and IV (10%); 17% of the strains were non-typable. All isolates were susceptible to penicillin, 96% to erythromycin and 97·5% to clindamycin. The emergence of new GBS serotypes has important implications for vaccine prevention strategies.

scholarly journals Developing a serocorrelate of protection against invasive group B streptococcus disease in pregnant women: a feasibility study

2019 ◽  
Vol 23 (67) ◽  
pp. 1-40 ◽  
Author(s):  
Clara Carreras-Abad ◽  
Madeleine Cochet ◽  
Tom Hall ◽  
Laxmee Ramkhelawon ◽  
Asma Khalil ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Feasibility Study ◽  
Group B Streptococcus ◽  
Serotype Distribution ◽  
Invasive Group ◽  
Streptococcal Disease ◽  
Group B Streptococcal Disease ◽  
Intrapartum Antibiotic ◽  
Group B ◽  
Operational Aspects

Background Group B streptococcus is the leading cause of infection in infants. Currently, intrapartum antibiotic prophylaxis is the major strategy to prevent invasive group B streptococcus disease. However, intrapartum antibiotic prophylaxis does not prevent maternal sepsis, premature births, stillbirths or late-onset disease. Maternal vaccination may offer an alternative strategy. Multivalent polysaccharide protein conjugate vaccine development is under way and a serocorrelate of protection is needed to expedite vaccine licensure. Objectives The ultimate aim of this work is to determine the correlate of protection against the major group B streptococcus disease-causing serotypes in infants in the UK. The aim of this feasibility study is to test key operational aspects of the study design. Design Prospective cohort study of pregnant women and their infants in a 6-month period (1 July to 31 December 2018). Setting Five secondary and tertiary hospitals from London and South England. National iGBS disease surveillance was conducted in all trusts in England and Wales. Participants Pregnant women aged ≥ 18 years who were delivering at one of the selected hospitals and who provided consent during the study period. There were no exclusion criteria. Interventions No interventions were performed. Main outcome measures (1) To test the feasibility of collecting serum at delivery from a large cohort of pregnant women. (2) To test the key operational aspects for a proposed large serocorrelates study. (3) To test the feasibility of collecting samples from those with invasive group B streptococcus. Results A total of 1823 women were recruited during the study period. Overall, 85% of serum samples were collected at three sites collecting only cord blood. At the two sites collecting maternal, cord and infant blood samples, the collection rate was 60%. A total of 614 women were screened for group B streptococcus with a colonisation rate of 22% (serotype distribution: 30% III, 25% Ia, 16% II, 14% Ib, 14% V and 1% IV). A blood sample was collected from 34 infants who were born to colonised women. Maternal and infant blood and the bacterial isolates for 15 newborns who developed invasive group B streptococcal disease during the study period were collected (serotype distribution: 29% III, 29% II, 21% Ia, 7% Ib, 7% IV and 7% V). Limitations Recruitment and sample collection were dependent on the presence of research midwives rather than the whole clinical team. In addition, individualised consent limited the number of women who could be approached each day, and site set-up for the national surveillance study and the limited time period of this feasibility study limited recruitment of all eligible participants. Conclusions We have verified the feasibility of collecting and processing rectovaginal swabs and blood samples in pregnant women, as well as samples from those with invasive group B streptococcal disease. We have made recommendations for the recruitment of cases within the proposed GBS3 study and for controls both within GBS3 and as an extension of this feasibility study. Future work A large case–control study comparing specific immunoglobulin G levels in mothers whose infants develop invasive group B streptococcal disease with those in colonised mothers whose infants do not develop invasive group B streptococcal disease is recommended. Trial registration Current Controlled Trials ISRCTN49326091; IRAS project identification number 246149/REC reference number 18/WM/0147. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 67. See the NIHR Journals Library website for further project information.

scholarly journals Whole Genome Sequence based Capsular Typing and Antimicrobial Resistance Prediction of Group B Streptococcal Isolates from Colonized Pregnant Women in Nigeria

2021 ◽  
Author(s):  
Mienye Bob-Manuel ◽  
Lesley McGee ◽  
Jeremiah Igunma ◽  
Mary Alex-Wele ◽  
Orikomaba Obunge ◽  
...  
Keyword(s):  
Antimicrobial Resistance ◽  
Pregnant Women ◽  
Whole Genome Sequencing ◽  
Genome Sequencing ◽  
Group B Streptococcus ◽  
Whole Genome Sequence ◽  
Whole Genome ◽  
Resistance Prediction ◽  
Group B ◽  
Capsular Typing

Abstract Background: Streptococcus agalactiae (Group B Streptococcus, GBS) is one of the major bacterial pathogens responsible for neonatal sepsis. Whole genome sequencing has, in recent years, emerged as a reliable tool for capsular typing and antimicrobial resistance prediction. This study characterized vaginal and rectal isolates of Group B Streptococcus obtained from pregnant women in Port Harcourt, Nigeria using a whole-genome sequence-based approach.Results: Capsular types Ia, Ib, II, III, IV and V were detected among the 43 isolates sequenced. Twelve sequence types (STs) were identified, with ST19 (n=9, 27.3%) and ST486 (n=5, 15.2%) the most frequent among non-duplicated isolates. Of the alpha-like proteins (alp) identified, Alp1 was the most prevalent in 11 (33.3%) isolates. Macrolide and lincosamide resistance determinants were present in 15 (45.5%) isolates; ermB was detected in 1 (3%) and ermTR in 7 (21.2%) isolates. The lnu gene, was detected in 6 (18.2%) and mef was identified in 3 (9.1%) isolates. Resistance of GBS to erythromycin and clindamycin was found to be 30.3% and 24.2%, respectively. All isolates were resistant to tetracycline with only the tetM gene identified. Fluoroquinolone-resistance conferring substitutions in gyrA + parC were detected in 9 (27.3%) isolates and chloramphenicol resistance was predicted in 11 (33.3%).Conclusion: The data available from the whole genome sequencing of these isolates offers a small but insightful description of common serotypes and resistance features within colonizing GBS in Nigeria.

scholarly journals Whole genome sequence based capsular typing and antimicrobial resistance prediction of Group B streptococcal isolates from colonized pregnant women in Nigeria

BMC Genomics ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Mienye Bob-Manuel ◽  
Lesley McGee ◽  
Jeremiah A Igunma ◽  
Mary A Alex-Wele ◽  
Orikomaba K Obunge ◽  
...  
Keyword(s):  
Antimicrobial Resistance ◽  
Pregnant Women ◽  
Whole Genome Sequencing ◽  
Genome Sequencing ◽  
Group B Streptococcus ◽  
Whole Genome Sequence ◽  
Whole Genome ◽  
Resistance Prediction ◽  
Group B ◽  
Capsular Typing

Abstract Background Streptococcus agalactiae (Group B Streptococcus, GBS) is one of the major bacterial pathogens responsible for neonatal sepsis. Whole genome sequencing has, in recent years, emerged as a reliable tool for capsular typing and antimicrobial resistance prediction. This study characterized vaginal and rectal isolates of Group B Streptococcus obtained from pregnant women in Port Harcourt, Nigeria using a whole-genome sequence-based approach. Results Capsular types Ia, Ib, II, III, IV and V were detected among the 43 isolates sequenced. Twelve sequence types (STs) were identified, with ST19 (n = 9, 27.3 %) and ST486 (n = 5, 15.2 %) the most frequent among non-duplicated isolates. Of the alpha-like proteins (alp) identified, Alp1 was the most prevalent in 11 (33.3 %) isolates. Macrolide and lincosamide resistance determinants were present in 15 (45.5 %) isolates; ermB was detected in 1 (3 %), ermTR in 7 (21.2 %) isolates, lnu gene was detected in 6 (18.2 %) and mef was identified in 3 (9.1 %) isolates. Resistance of GBS to erythromycin and clindamycin (predicted from presence of erm or mef genes) was found to be 30.3 % and 24.2 %, respectively. All isolates were predicted resistant to tetracycline with only the tetM gene identified. Fluoroquinolone-resistance conferring substitutions in gyrA + parC were detected in 9 (27.3 %) isolates and chloramphenicol resistance was predicted from presence of aac6’-aph2 gene in 11 (33.3 %). Conclusions The data available from the whole genome sequencing of these isolates offers a small but insightful description of common serotypes and resistance features within colonizing GBS in Nigeria.

Sign in / Sign up

Export Citation Format

Share Document